|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Guidelines to authors
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
INFORMATION FOR AUTHORS
European Journal of Clinical Pharmacy®, is a peer reviewed biomedical journal that publish papers related to clinical pharmacy, clinical pharmacology, pharmacoepidemiology, pharmacoeconomics, pharmacotherapy and clinical management in the following sections, not necessary included in every issue.
Opinion expressions about controversies or interest aspects, both scientifically or health and pharmaceutical management. Usually editorials are solicitated to the author by the editorial committee and its extension would be not more than 1,200 words. If an editorial would be proposed for publication, please contact before with the editorial committee.
Experimental papers with the following general structure: Introduction, methods, results and discussion.
Bibliographic compilation paper with the main objective to establish the state of the art of the know ledge of one drug, a drug’s group, illness treatment or every aspect related to medicines or clinical management. The paper will be developed with critical analysis and comparative. In the conclusions would remark some clinical practice advices.
Paper with a limited extension to 1,500 words, two tables and/or figures, with not more than 20 references. Usually are included in this section: Clinical reports, preliminary communications, and some experiences with a reduced number of cases (side effects, drug interactions, etc.).
Letters to Editor
Brief opinion’s expression, with not more than 300 words, one table and/or figure, with not more than 5 references. Usually are included in this section: General interest opinions, comments for a paper published before, etc. In this case European Journal of Clinical Pharmacy® will send a copy to the authors for the possible reply.
Editors and reviewers spend many hours reading manuscripts, and therefore appreciate receiving manuscripts that are easy to read and edit.
MAILING THE SUBMISSION
1. For preparing a manuscript for submission to a biomedical journal, European Journal of Clinical Pharmacy is following the Uniform Requirements for Manuscripts Submitted to Biomedical Journals published by the International Committee of Journal Medical Editors (ICMJE) (http://www.icmje.org/manuscript_1prepare.html)
2. The manuscripts will be submitt by our website : www.farmclin.com
and correspondence will be send by email to: email@example.com
1. The text of observational and experimental articles is usually, divided into the following sections: Introduction, Methods, Results, and Discussion. This so-called “IMRAD” structure is not an arbitrary publication format but rather a direct reflection of the process of scientific discovery. Long articles may need subheadings within some sections (especially Results and Discussion) to clarify their content. Other types of articles, such as case reports, reviews, and editorials, probably need to be formatted differently.
2. Double-spacing all portions of the manuscript— including the title page, abstract, text, acknowledgments, references, individual tables, and legends—and generous margins make it possible for editors and reviewers to edit the text line by line and add comments. As manuscripts are submitted electronically, the files should be double-spaced to facilitate reviewing and editing.
3. The authors will have to certify that the presented works are unpublished and have not been sent simultaneously to other journals for his publication. This does not exclude the publication of complete works later to the publication of previous findings as summaries, letters and preliminary communications. In this case a copy of the publication will be attached to the presented manuscript.
4. The works will have to be written in English language, with the abstract summarize in English and Spanish. The manuscripts will be written in electronic format by the publishers of text Microsoft Word version 2.0 or superior, to double space, size of page DIN A-4 and the margins to 2,5 cm.
5. All the pages will take a correlative numeration in the top right angle, beginning for the page of the title and including the tables and figures. Every part of the work will begin in a new page in the following order.
The title page should have the following information:
1. Article title. Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized, controlled trials). Authors should include all information in the title that will make electronic retrieval of the article both sensitive and specific.
2. Authors’ names and institutional affiliations with author’s highest academic degree(s).
3. The name of the department(s) and institution(s) to which the work should be attributed.
4. Disclaimers, if any.
5. Contact information for corresponding authors. The name, mailing address, telephone and fax numbers, and e-mail address of the author responsible for correspondence about the manuscript. The corresponding author could indicate whether his or her e-mail address can be published.
6. The name and address of the author to whom requests for reprints should be addressed or a statement that reprints are not available from the authors.
7. Source(s) of support in the form of grants, equipment, drugs, or all of these.
Conflict of Interest Notification Page
To prevent potential conflicts of interest from being overlooked or misplaced, this information needs to be part of the manuscript. The ICMJE has developed a uniform disclosure form for use by ICMJE member journals.
1. Structured abstracts are preferred for original research and systematic reviews. The abstract should provide the context or background for the study and should state the study’s purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), principal conclusions, and funding sources. It should emphasize new and important aspects of the study or observations.
2. Because abstracts are the only substantive portion of the article indexed in many electronic databases, and the only portion many readers read, authors need to be careful that they accurately reflect the content of the article.
3. Later of the summary, three will be three to ten key words that should allow to identify the content. One advises to use the terms of Medical Subject Headins (MeSH) of the Index Medicus.
1. Provide a context or background for the study (that is, the nature of the problem and its significance). State the specific purpose or research objective of, or hypothesis tested by, the study or observation; the research objective is often more sharply focused when stated as a question. Both the main and secondary objectives should be clear, and any prespecified subgroup analyses should be described. Provide only directly pertinent references, and do not include data or conclusions from the work being reported.
1. The Methods section should include only information that was available at the time the plan or protocol for the study was being written; all information obtained during the study belongs in the Results section.
2. Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population. Because the relevance of such variables as age and sex to the object of research is not always clear, authors should explain their use when they are included in a study report—for example, authors should explain why only participants of certain ages were included or why women were excluded. The guiding principle should be clarity about how and why a study was done in a particular way.
3. Identify the methods, apparatus (give the manufacturer’s name and address in parentheses), and procedures in sufficient detail to allow others to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well-known; describe new or substantially modified methods, give the reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration.
4. Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as P values, which fail to convey important information about effect size. References for the design of the study and statistical methods should be to standard works when possible (with pages stated). Define statistical terms, abbreviations, and most symbols. Specify the computer software used.
1. Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat all the data in the tables or illustrations in the text; emphasize or summarize only the most important observations. Extra or supplementary materials and technical detail can be placed in an appendix where they will be accessible but will not interrupt the flow of the text, or they can be published solely in the electronic version of the journal.
2. When data are summarized in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated, and specify the statistical methods used to analyze them. Restrict tables and figures to those needed to explain the argument of the paper and to assess supporting data. Do not duplicate data in graphs and tables. Avoid nontechnical uses of technical terms in statistics, such as “random” (which implies a randomizing device), “normal,” “significant,” “correlations,” and “sample.” Where scientifically appropriate, analyses of the data by such variables as age and sex should be included.
1. Emphasize the new and important aspects of the study and the conclusions that follow from them in the context of the totality of the best available evidence. Do not repeat in detail data or other information given in the Introduction or the Results section. For experimental studies, it is useful to begin the discussion by briefly summarizing the main findings, then explore possible mechanisms or explanations for these findings, compare and contrast the results with other relevant studies, state the limitations of the study, and explore the implications of the findings for future research and for clinical practice.
2. Link the conclusions with the goals of the study but avoid unqualified statements and conclusions not adequately supported by the data. In particular, avoid making statements on economic benefits and costs unless the manuscript includes the appropriate economic data and analyses. Avoid claiming priority or alluding to work that has not been completed. State new hypotheses when warranted, but label them clearly as such.
1. Although references to review articles can be an efficient way to guide readers to a body of literature, review articles do not always reflect original work accurately. Readers should therefore be provided with direct references to original research sources whenever possible. On the other hand, extensive lists of references to original work on a topic can use excessive space on the printed page. Small numbers of references to key original papers often serve as well as more exhaustive lists, particularly since references can now be added to the electronic version of published papers, and since electronic literature searching allows readers to retrieve published literature efficiently.
2. Avoid using abstracts as references. References to papers accepted but not yet published should be designated as “in press” or “forthcoming”; authors should obtain written permission to cite such papers as well as verification that they have been accepted for publication. Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source.
3. Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, obtain written permission and confirmation of accuracy from the source of a personal communication.
4. Some but not all journals check the accuracy of all reference citations; thus, citation errors sometimes appear in the published version of articles. To minimize such errors, references should be verified using either an electronic bibliographic source, such as PubMed or print copies from original sources. Authors are responsible for checking that none of the references cite retracted articles except in the context of referring to the retraction. For articles published in journals indexed in MEDLINE, the ICMJE considers PubMed the authoritative source for information about retractions. Authors can identify retracted articles in MEDLINE by using the following search term, where pt in square brackets stands for publication type: Retracted publication [pt] in PubMed.
5. The Uniform Requirements style for references is based largely on an American National Standards Institute style adapted by the NLM for its databases. Authors should consult NLM’s Citing Medicine for information on its recommended formats for a variety of reference types. Authors may also consult sample references, a list of examples extracted from or based on Citing Medicine for easy use by the ICMJE audience; these sample references are maintained by NLM.
Solter Na, Wasserman Si, Auster KF. Cold urticaria: release into the circulation of histamine and eosinophile chemotactic factor of anaphilaxis during cold challenge. N Engl J Med 1997; 294: 487-9.
Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Pathology. Recommended method for the determination of gamma-glutamyltransferase in blood. Scand J Clin Lab Invest 1996; 36:119-25.
Shen HM, Zhang QF. Risk assessment of nickel carcinogenicity and occupational lung cancer. Environ Health Perspect 1994; 102 (Supl 1): 275-82.
Books and Monographs
Ringver MK, Bond D. Gerontology and leadership skills fur nurses. 2d ed. Albany, NY; Delmar; 1996.
Rhode AJ, Van Rooyce CE, eds. Text-book of virology for students and practitioners of medicine and other health sciences. 5th ed. Baltimore: Williams & Wilkins; 1968.
Chapter of a book
Weinstein L; Swartz N: Pathogenic properties of invading microorganisms. In: Sodeman WA Jt, Soderman WA, Eds. Pathologic physiology: Mechanisms of disease. Philadelphia: WB Saunders; 1974: 457-72.
Work of a Congress/ symposium/International Meeting
Cuzzy CE Jr, Antal EG, Keys PW et al. The drug-specific audit: Another tool for pharmacy. Presented at the 13th Annual ASHP Midyear Clinical Meeting, 5th December 1978, San Antonio TX.
MediMedia-Medicom. Vademecum International [on line]. Madrid: 39th edition. Madrid: MediMediaMedicom, 1998, Electronic version of the catalog of same name. http://vademecum.medicom.es/ [Consulted: 14th January 1999].
Fuincham JE. “The role and economic impact of pharmacists care” [on line]. Journal of Pharmaceutical Care. Vol 1, article 1 (1997). Electronic Journal http://22.214.171.124/pharmacay/jpc/jp10101.htm [Consult: 2th February 1999].
Electronic Documents: Implications for Libraries. The Public.Acces Computer Systems Review [on line]. 1994, vol 5, no. 3 pp. 5-21. Internet: [Consulted: 28th July 1994].
6. References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals in parentheses. References cited only in tables or figure legends should be numbered in accordance with the sequence established by the first identification in the text of the particular table or figure. The titles of journals should be abbreviated according to the style used in the list of Journals Indexed for MEDLINE, posted by the NLM on the Library's Web site. Journals vary on whether they ask authors to cite electronic references within parentheses in the text or in numbered references following the text.
1. Tables capture information concisely and display it efficiently; they also provide information at any desired level of detail and precision. Including data in tables rather than text frequently makes it possible to reduce the length of the text.
2. Type or print each table with double-spacing on a separate sheet of paper. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Do not use internal horizontal or vertical lines. Give each column a short or an abbreviated heading. Authors should place explanatory matter in footnotes, not in the heading. Explain all nonstandard abbreviations in footnotes, and use the following symbols, in sequence:
*, †, ‡, §, ||, ¶, **, ††, ‡‡, §§, ||||, ¶¶, etc.
3. Identify statistical measures of variations, such as standard deviation and standard error of the mean.
4. Be sure that each table is cited in the text.
5. If you use data from another published or unpublished source, obtain permission and acknowledge that source fully.
6. Additional tables containing backup data too extensive to publish in print may be appropriate for publication in the electronic version of the journal, deposited with an archival service, or made available to readers directly by the authors. An appropriate statement should be added to the text to inform readers that this additional information is available and where it is located. Submit such tables for consideration with the paper so that they will be available to the peer reviewers.
1. Figures should be either professionally drawn and photographed, or submitted as photographic-quality digital prints. In addition to requiring a version of the figures suitable for printing, some journals now ask authors for electronic files of figures in a format (for example, JPEG or GIF) that will produce high-quality images in the Web version of the journal; authors should review the images of such files on a computer screen before submitting them to be sure they meet their own quality standards.
2. For x-ray films, scans, and other diagnostic images, as well as pictures of pathology specimens or photomicrographs, send sharp, glossy, black-and-white or color photographic prints, usually 127 x 173 mm (5 x 7 inches). Although some journals redraw figures, many do not. Letters, numbers, and symbols on figures should therefore be clear and consistent throughout, and large enough to remain legible when the figure is reduced for publication. Figures should be made as self-explanatory as possible, since many will be used directly in slide presentations. Titles and detailed explanations belong in the legends--not on the illustrations themselves.
3. Photomicrographs should have internal scale markers. Symbols, arrows, or letters used in photomicrographs should contrast with the background.
4. Photographs of potentially identifiable people must be accompanied by written permission to use the photograph.
5. Figures should be numbered consecutively according to the order in which they have been cited in the text. If a figure has been published previously, acknowledge the original source and submit written permission from the copyright holder to reproduce the figure. Permission is required irrespective of authorship or publisher except for documents in the public domain.
6. For illustrations in colour, ascertain whether the journal requires colour negatives, positive transparencies, or colour prints. Accompanying drawings marked to indicate the region to be reproduced might be useful to the editor. Some journals publish illustrations in colour only if the author pays the additional cost.
7. Authors should consult the journal about requirements for figures submitted in electronic formats.
Legends for Illustrations (Figures)
1. Type or print out legends for illustrations using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend. Explain the internal scale and identify the method of staining in photomicrographs.
Units of Measurement
1. Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or litter) or their decimal multiples.
2. Temperatures should be in degrees Celsius. Blood pressures should be in millimetres of mercury. Journals vary in the units they use for reporting hematologic, clinical chemistry, and other measurements. Authors must consult the Information for Authors of the particular journal and should report laboratory information in both local and International System of Units (SI). Editors may request that authors add alternative or non-SI units, since SI units are not universally used. Drug concentrations may be reported in either SI or mass units, but the alternative should be provided in parentheses where appropriate.
Abbreviations and Symbols
1. Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement.
Intellectual Property/ Copyright
1. Any Author/s, who submits a paper, expressly acknowledges and accepts at the precise time that he/she/they is/are submitting his/her/their paper, the European Journal of Clinical Pharmacy® to be a collective work as defined by the Spanish Royal Legislative Decree 1/1996 of 12th of April, approving the revised text of the Copyright Act, which regulates, clarifies and harmonizes the existing legislation on the subject, currently in force.
The Spanish Copyright Act sets forth that, except otherwise agreed, the rights upon a collective work shall vest in the person who publishes and discloses it using its name. Such person is here Rasgo Editorial S.L. and the Author/s expressly agrees and acknowledges to be already aware of it, or otherwise to be here well informed in this regard. In addition to the cited acknowledgment set forth by Spanish law, any Author/s, who submits a paper, expressly acknowledges and accepts at the precise time that he/ she/they is/are submitting his/her/their paper to European Journal of Clinical Pharmacy® , all rights upon his/her/their submitted paper to vest in Rasgo Editorial, S.L., as set forth regarding collective works by the Spanish Copyright Act. Consequently, after a paper is submitted by an Author/s, Rasgo Editorial, S.L. shall be able to reproduce, distribute and publicly communicate it (also in the form of making it available to the public through the Internet), in any and all existing formats and devices, during the whole legal life of the rights and in all territories in the world.
2. Any Author/s, who submits a paper, expressly agrees and accepts at the precise time that he/she/they is/are submitting his/her/their paper, that Rasgo Editorial S.L. will be entitled to exploit the rights set forth in the previous Paragraph upon any paper submitted by the Author/s, either by itself or by means of third parties, either within a journal, or also in a separated form without forming part of the journal, without the Author/s being able to exploit his/her/their submitted paper on his/her/their own.
3. Any Author/s, who submits a paper, expressly acknowledges and accepts at the precise time that he/she/their is/are submitting his/her/their paper, that because of the nature and practices within the market of journals as the European Journal of Clinical Pharmacy® , the increase of the reputation of the Author/s as researcher, when publishing in the journal, is a satisfying remuneration for the contribution of the Author/s. With this regard the Author/s expressly agrees and accepts not to have any further remuneration/s to claim to Rasgo Editorial, S.L. for any of the rights to which this company will be entitled to.
4. Any Author/s, who submits a paper, declares to have accurately read these terms and conditions and he/she/they expressly agrees with Rasgo Editorial S.L. the above provisions, terms and conditions, and their legal consequences, are subject to Spanish laws, and that in case of any dispute arising or derived of, or related to, their contribution, the competent jurisdiction to resolve them shall be the courts and tribunals of Spain.